Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KW-0761 in previously treated PTCL and CTCL
NCT00888927Phase 2Completed
- Sponsor
- Kyowa Kirin
- Start
- May 2009
- Primary completion
- Sep 2012
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of mogamulizumab in peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) (4 arms), sponsored by Kyowa Kirin. Primary endpoint: Maximum Tolerated Dose at 6 weeks. Started May 2009; status: completed.
02
Drugs
mogamulizumab
03
Conditions
peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT00888927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00888927.